000168069 001__ 168069
000168069 005__ 20260202145621.0
000168069 0247_ $$2doi$$a10.1016/j.jacl.2014.06.002
000168069 0248_ $$2sideral$$a87730
000168069 037__ $$aART-2014-87730
000168069 041__ $$aeng
000168069 100__ $$0(orcid)0000-0001-9142-0737$$aJarauta,E.$$uUniversidad de Zaragoza
000168069 245__ $$aAtherosclerosis progression in patients with autosomal dominant hypercholesterolemia in clinical practice
000168069 260__ $$c2014
000168069 5203_ $$aBackground: Autosomal dominant hypercholesterolemias (ADH) are associated with high risk of premature cardiovascular disease (CVD). No data on progression of atherosclerosis in ADH population in clinical practice are available.
Objective: To investigate atherosclerosis progression in ADH patients and its relationship with CVD risk factors.
Methods: A total of 463 patients, 279 with familial hypercholesterolemia and 184 with familial combined hyperlipidemia, were prospectively followed during a median of 36.5 months. Carotid intima-media thickness (cIMT) was assessed at baseline and at the end of the follow-up by ultrasonography.
Results: A total of 259 patients (55.9%) showed cIMT progression and 149 (32.2%) remained within normal age-adjusted cIMT. Baseline cIMT was the variable most inversely associated with cIMT progression (B = -0.313; P < .001). Hypertension, diabetes, and smoking during follow-up were variables positively associated with progression. Patients who began statin treatment during the study period had less progression than former statin users. The 83.7% of ADH with normal baseline cIMT, absence of major CVD risk factors and non–high-density lipoprotein (HDL) cholesterol <190 mg/dL at follow-up remained with normal cIMT at the end of the study. Non-HDL cholesterol concentration reached during the follow-up was associated with cIMT only in subjects with abnormal cIMT at baseline. In this subgroup, cIMT tended to avoid progression with non-HDL cholesterol <130 mg/dL.
Conclusion: Atherosclerosis progression varies greatly among ADH patients. cIMT progression was inversely related to baseline cIMT and previous use of statins, and positively with age and CVD risk factors during the follow-up. Patients previously treated with statins may not be the preferred candidates for atherosclerosis regression trials. Treatment recommendations in ADH should be based on baseline risk.
000168069 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000168069 590__ $$a3.904$$b2014
000168069 591__ $$aPHARMACOLOGY & PHARMACY$$b44 / 255 = 0.173$$c2014$$dQ1$$eT1
000168069 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000168069 700__ $$0(orcid)0000-0001-6650-8294$$aGallego,R. M.
000168069 700__ $$aBea,A. M.
000168069 700__ $$aCrespo,M.
000168069 700__ $$aBallester,A.
000168069 700__ $$aRubio,V.
000168069 700__ $$aRueda,L. B.
000168069 700__ $$aCalmarza,P.
000168069 700__ $$aCenarro,A.
000168069 700__ $$aDe Groot,E.
000168069 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira,F.$$uUniversidad de Zaragoza
000168069 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000168069 773__ $$g8, 4 (2014), 373-380$$pJournal of Clinical Lipidology$$tJournal of Clinical Lipidology$$x1933-2874
000168069 8564_ $$s332132$$uhttps://zaguan.unizar.es/record/168069/files/texto_completo.pdf$$yVersión publicada
000168069 8564_ $$s2142548$$uhttps://zaguan.unizar.es/record/168069/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000168069 909CO $$ooai:zaguan.unizar.es:168069$$particulos$$pdriver
000168069 951__ $$a2026-02-02-14:49:04
000168069 980__ $$aARTICLE